Clinical Topics

New VA Analysis Refutes Link Between Heart Failure, Incident Cancer

by Brenda Mooney

August 11, 2018

BOSTON—With about 350,000 patients with heart failure diagnoses being treated in the VHA, recent studies suggesting that the cardiovascular condition increases risk of cancer have been worrisome.

Among the first of those was an article in the Journal of the American College of Cardiology, which concluded HF patients had a 68% higher risk of developing cancer (hazard ratio [HR]: 1.68; 95% CI: 1.13 to 2.50) adjusted for body mass index, smoking and comorbidities. “HF patients are at increased risk of cancer, which appears to have increased over time. Cancer increases mortality in HF, underscoring the importance of noncardiac morbidity and of cancer surveillance in the management of HF patients,” stated the Mayo Clinic researchers.1

A new study published online by the same journal has called that research into question, however. VA Boston Healthcare System researchers and colleagues suggested the trials might have been “constrained by limited size and follow-up, lack of comprehensive data on other health attributes, and adjudicated cancer outcomes.”2

The study team, which included researchers from the Hospital of the University of Pennsylvania in Philadelphia and Brigham and Women’s Hospital in Boston, among others, sought to determine to what degree HF is associated with cancer incidence and cancer-specific mortality.

Cohorts from the Physicians’ Health Studies I and II, 2 randomized controlled trials of aspirin and vitamin supplements conducted from 1982 to 1995 and from 1997 to 2011, respectively, were used to do that. Those trials included annual health evaluations and determination of cancer and HF diagnoses. The focus was on the 1,420 of the 28,341 Physicians’ Health Study participants who developed HF.

Data Analysis

The data was analyzed several ways. In the primary analysis, the study excluded participants with cancer or HF at baseline and performed multivariable-adjusted Cox models to determine the relationship between HF and cancer, modeling HF as a time-varying exposure. In a complementary analysis, the study used the landmark method and identified cancer-free participants at 70 years of age, differentiating with and without HF, performing Cox regression. In addition, sensitivity analyses were performed.

Overall, 7,363 cancers developed during a median follow-up time of 19.9 years (25th to 75th percentile: 11.0 to 26.8 years) in the group. HF was not associated with cancer incidence in crude (hazard ratio: 0.92; 95% confidence interval: 0.80 to 1.08) or multivariable-adjusted analysis (hazard ratio: 1.05; 95% confidence interval: 0.86 to 1.29), however.

In addition, the researchers reported, no association was found between HF and site-specific cancer incidence or cancer-specific mortality after multivariable adjustment. Results were similar when using the landmark method at all landmark ages, they added.

“HF is not associated with an increased risk of cancer among male physicians,” the study authors concluded.

A review in the European Journal of Heart Failure earlier this year attempted to explain the contradictory information on whether HF increases cancer risk. “This finding may be due to a surveillance bias, since active follow‐up of HF patients with regular visits may result in detection of tumors at an early stage, which is missed in the general population. Silent malignancies may be discovered by exams routinely performed for HF management (e.g., red blood cell count revealing anemia due to primary or secondary neoplastic infiltration of the bone marrow or chest X‐ray showing a pulmonary nodule).

“It is also possible that HF therapies render clinically overt tumors that would be otherwise asymptomatic: this may be for instance the case with prostate carcinoma being revealed by difficult voiding in response to diuretics, or intestinal neoplasms that start to bleed due to chronic anti‐thrombotic treatment,” the Italian authors wrote. “Strikingly, these scenarios are well known by clinical practice, but have not actually been put in evidence by the scientific literature. On the other hand, symptoms due to a tumor may overlap with those of HF and be attributed to heart disease. This may even delay cancer diagnosis, as symptoms might be thought of as due to advancing disease rather than new cancer.”

1. Hasin T, Gerber Y, McNallan SM, Weston SA, et. al. Patients with heart failure have an increased risk of incident cancer. J Am Coll Cardiol. 2013 Sep 3;62(10):881-6. doi: 10.1016/j.jacc.2013.04.088. Epub 2013 Jun 27. PubMed PMID: 23810869; PubMed Central PMCID: PMC3758775.

2. Selvaraj S, Bhatt DL, Claggett B, Djoussé L, et. Al. Lack of Association Between Heart Failure and Incident Cancer. J Am Coll Cardiol. 2018 Apr 10;71(14):1501-1510. doi: 10.1016/j.jacc.2018.01.069. PubMed PMID: 29622155.

3. Ameri P, Canepa M, Anker MS, Belenkov Y,et. al. Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail. 2018 May;20(5):879-887. doi: 10.1002/ejhf.1165. Epub 2018 Feb 21. Review. PubMed PMID:29464808.

Comments are closed here.

Related Articles

Right actions in the future are the best apologies for bad actions in the past. Tryon Edwards (1809-1894)

The Department of Defense recently underwent an internal review of opioid use within three major military treatment facilities through the Inspector General office. The report remains preliminary and has not yet been released to the... View Article

New Device Improves Balance in 100% of Veterans with Gulf War Illness

A new device that corrects vestibular dysfunction could be a key to treating many of the symptoms affecting the approximately 300,000 veterans who suffer from Gulf War Illness.

U.S. Medicine Recommends

More From cardiology


NASA Partners with Academia for CVD Prediction Tool in Younger Adults

Federal medicine played a crucial role in the development of a new online tool to better predict which middle-aged adults are at the greatest risk of having acute myocardial infarction or stroke over the next decade.


VA Research Determines Which Beta Blocker Is Better in Heart Failure

PALO ALTO, CA—This likely will come as little surprise to healthcare professionals who soldiered through it, but the 2017-18 influenza season was the most severe since VA surveillance was initiated in 2009. VA conducts yearly... View Article


Medications, interventions underused in veterans with peripheral artery disease

Nearly 30% of veterans with peripheral artery disease (PAD) die within four years of diagnosis, while others experience limb amputation or critical limb ischemia.


Rank as socioeconomic proxy affects stroke outcomes in MHS patients

Do socioeconomic disparities exist in the U.S. military healthcare system with ischemic stroke admissions? A new study says they do.


In-Hospital Cardiac Arrest Has Higher Survival Rates at VA Hospitals

Veterans who suffer cardiac arrest during a VA hospital stay are more likely to survive the experience than patients who have such events cardiac arrests in other U.S. hospitals. And, a year later, they are also more likely to still be alive.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up